Minerva Neurosciences reported $28.08M in Equity Capital and Reserves for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Acadia Pharmaceuticals ACAD:US $ 566.96M 2.12M
Adma Biologics ADMA:US $ 102.78M 8.81M
ALKERMES ALKS:US $ 1096.17M 1.73M
Arena Pharmaceuticals ARNA:US $ 800.72M 170.36M
AstraZeneca AZN:LN 39744M 24068M
Biocryst Pharmaceuticals BCRX:US $ -147.04M 40.97M
Bristol Myers Squibb BMY:US $ 37213M 405M
Dynavax Technologies DVAX:US $ 67.58M 15.8M
Eli Lilly And LLY:US $ 7757M 1312.6M
Esperion Therapeutics ESPR:US $ -362705000 58.4M
GlaxoSmithKline GSK:LN 15426M 49M
Halozyme Therapeutics HALO:US $ 281.67M 161.93M
Kindred Biosciences KIN:US $ 79.77M 4.02M
Marinus Pharmaceuticals MRNS:US $ 78.49M 16.57M
Minerva Neurosciences NERV:US $ 28.08M 8.09M
Neurocrine Biosciences NBIX:US $ 1346M 66.8M
Novartis NOVN:VX SF 56771M 2729M
Novavax NVAX:US $ 461.34M 284.23M
Takeda 4502:JP Y 5323935M 24161M
Vanda Pharmaceuticals VNDA:US $ 493.32M 12.1M